Overview Myasthenia gravis (MG) is a rare chronic neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. With the earliest accounts dating back to the late 1600s, 287 MG is described as an autoimmune disorder affecting neuromuscular junctions. Thought to arise as a result of the body generating antibodies against the acetylcholine receptor (AChR) or muscle specific kinase, resulting in the immune system mistakenly attacking receptors on muscle cells, particularly at the neuromuscular junction where nerve impulses stimulate muscle contractions, MG leads to muscle weakness and a host of other symptoms. During the Covid-19 pandemic, reports have emerged of onset of MG after SARS-Cov-2 infection. Global prevalence rates range from 150 to 200 cases per 1,000,000 people. The prevalence of MG in the United States is estimated at 14 to 20 cases per every 100,000 people or between 36,000 and 60,000 cases. In Europe, an estimated 56,000 to 123,000 individuals live with MG. The hallmark symptom of MG is muscle weakness, which typically worsens with activity and improves with rest. This weakness can affect various muscles, including those controlling eye movements, facial expressions, chewing, swallowing, and breathing. Fatigue is also a common feature, with muscles becoming progressively weaker during periods of activity. Weakness in the muscles that control eye movements often leads to double vision or drooping of the eyelids (ptosis). Difficulty swallowing (dysphagia) can occur due to weakness in the muscles involved in chewing and swallowing. In severe cases, weakness of the muscles involved in breathing can lead to respiratory difficulties, which can be life-threatening. Symptoms of MG can vary widely among individuals and may fluctuate over time, making diagnosis challenging. Factors such as stress, illness, fatigue, or certain medications can exacerbate symptoms in people with MG. Diagnosis typically involves a thorough medical history, physical examination, blood tests to check for specific antibodies associated with MG, and specialized tests such as electromyography and nerve conduction studies. While there is no cure for MG, various treatments can help manage symptoms and improve quality of life. These may include medications such as acetylcholinesterase (AChE) inhibitors, immunosuppressants, and corticosteroids. Some individuals may also benefit from procedures such as plasmapheresis or intravenous immunoglobulin therapy. In severe cases, surgical removal of the thymus gland (thymectomy) may be recommended. With appropriate treatment, many people with MG can lead fulfilling lives. However, the course of the disease can be unpredictable, and long-term management often requires close monitoring and adjustments to treatment by developing a personalized treatment plan and receive ongoing support and care.